Overall survival of early-stage gastric pure (de novo) DLBCL patients receiving frontline antibiotics and chemotherapy, and gastric DLBCL(MALT) patients receiving frontline antibiotics. Overall survival was calculated from the date of initial treatment to the date of death because of any cause by Kaplan-Meier analysis (antibiotic-treated pure [de novo] DLBCL vs DLBCL[MALT]; P = .882, 2-sided, log-rank test; pure [de novo] DLBCL with antibiotics vs chemotherapy; P = .551, 2-sided, log-rank test). HPE indicates HPE therapy as a frontline treatment; and CT, chemotherapy as a frontline treatment.